Binds Virus Or Component Or Product Thereof (e.g., Virus-associated Antigen, Etc.) Patents (Class 530/388.3)
-
Publication number: 20100080813Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that bind to hemagglutinin and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: ApplicationFiled: July 27, 2009Publication date: April 1, 2010Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Patent number: 7666420Abstract: The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV/HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 receptor of the soluble fraction of the Env protein of MSRV/HERV-W.Type: GrantFiled: January 24, 2005Date of Patent: February 23, 2010Assignees: Biomerieux, Institut National de la Sante et de la Recherche MedicaleInventors: Patrice Marche, Alexandre Rolland, Evelyne Jouvin-Marche, Herve Perron
-
Patent number: 7635476Abstract: Chimpanzee monoclonal antibodies and antigen binding fragments including a ?1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.Type: GrantFiled: April 23, 2007Date of Patent: December 22, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Darren J. Schofield, Suzanne U. Emerson, Robert Purcell, II
-
Publication number: 20090312527Abstract: Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. Various monoclonal antibodies recognizing specific epitope for specific HPV protein or HPV type, common epitope for various HPV proteins or HPV types are obtained. These obtained monoclonal antibodies are useful tools in early clinical detection of HPV infection and general detection of HPV related diseases, specific detection of invasive cervical cancer, detection of other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression.Type: ApplicationFiled: June 10, 2009Publication date: December 17, 2009Applicant: NEODIAGNOSTIC LABS INCInventor: Shuling Cheng
-
Patent number: 7632497Abstract: The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function. In particular, the molecules of the invention have an increased effector cell function mediated by a Fc?R, such as, but not limited to, ADCC. In one embodiment, the variant Fc region binds Fc?RIIIA and/or Fc?RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region.Type: GrantFiled: November 10, 2005Date of Patent: December 15, 2009Assignee: MacroGenics, Inc.Inventor: Jeffery Stavenhagen
-
Patent number: 7629443Abstract: The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.Type: GrantFiled: February 8, 2006Date of Patent: December 8, 2009Assignee: New York Blood Center, Inc.Inventors: Shibo Jiang, Yuxian He
-
Publication number: 20090291428Abstract: The invention encompasses an antibody that binds to and substantially inhibits the activity of at least one poxvirus complement inhibitor. Additionally, the application encompasses methods of detecting a poxvirus complement inhibitor and methods of decreasing the activity of a poxvirus complement inhibitor.Type: ApplicationFiled: May 20, 2009Publication date: November 26, 2009Applicant: The Washington UniversityInventors: John P. Atkinson, M. Kathryn Liszewski, Marilyn K. Leung, Paula Bertram
-
Patent number: 7622112Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.Type: GrantFiled: December 6, 2004Date of Patent: November 24, 2009Inventors: Jody Berry, Steven Jones, Xin Yong Yuan, Mike Gubbins, Anton Andonov, Hana Weingartl, Mike Drebot, Frank Plummer
-
Publication number: 20090280507Abstract: The present invention provides a method for measuring SARS virus nucleocapsid protein (SARS-NP) using first and second antibodies both binding specifically to SARS-NP, wherein the first or second antibody is an antibody recognizing an epitope located in a region (Region C) of amino acid 283 to 422 from the N-terminus of the amino acid sequence of SARS-NP.Type: ApplicationFiled: October 11, 2006Publication date: November 12, 2009Applicant: SYSMEX CORPORATIONInventors: Kotaro Fujimoto, Tadahiro Kajita, Kazuhiko Takeda, Takashi Okamoto
-
Publication number: 20090226433Abstract: The present invention provides novel human anti-influenza antibodies and related compositions and methods. These antibodies are used in the diagnosis and treatment of influenza infection.Type: ApplicationFiled: November 12, 2008Publication date: September 10, 2009Applicant: SPALTUDAQ CORP.Inventors: Andres Grandea, III, Gordon King, Thomas Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle
-
Patent number: 7579446Abstract: The invention provides binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. The invention further provides nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. Preferably, they can be used in the post-exposure prophylaxis of rabies.Type: GrantFiled: October 31, 2006Date of Patent: August 25, 2009Assignee: Crucell Holland B.V.Inventors: Alexander B. H. Bakker, Willem E. Marissen, Robert A. Kramer, Cornelius A. de Kruif
-
Publication number: 20090191536Abstract: Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the “a” determinant region of HBsAg.Type: ApplicationFiled: October 27, 2008Publication date: July 30, 2009Inventors: David Ying Chien, Yiu-Lian Fong, Azita Tabrizi, Heather Todd, Mark David Van Cleve
-
Publication number: 20090186023Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.Type: ApplicationFiled: March 20, 2009Publication date: July 23, 2009Inventors: Marie-Anne Petit, Colette Jolivet-Raynaud
-
Publication number: 20090130120Abstract: Individual monoclonal antibodies and fragments that bind a conserved epitope of the G protein of RSV and which are minimally immunogenic when administered to a human subject, are useful in treating RSV infections.Type: ApplicationFiled: October 24, 2008Publication date: May 21, 2009Inventors: Lawrence M. KAUVAR, Ellen J. Collarini, Bruce Keyt, Orit Foord
-
Publication number: 20090104207Abstract: The invention relates to anti-HCV antibodies and more specifically to neutralizing anti-HCV antibodies and their variable and complementarity determining regions (CDR). In particular, the neutralizing anti-HCV antibodies are neutralizing anti-HCV envelope protein 1 (HCV E1) antibodies. Also subject of the invention are compositions comprising these antibodies, CDRs or variable regions, and compounds comprising at least one of the CDRs or variable regions of said antibodies. Further subject of the invention are the application of any of said antibodies, CDRs, variable regions or compounds in HCV prophylaxis, therapy, and diagnosis, as well as methods for producing the antibodies.Type: ApplicationFiled: March 22, 2007Publication date: April 23, 2009Inventors: Erik Depla, Robert Purcell, Jens Bukh, Suzanne Emerson, Jens-Christophe Meunier
-
Publication number: 20090092620Abstract: The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group.Type: ApplicationFiled: October 7, 2008Publication date: April 9, 2009Applicant: SANOFI PASTEURInventors: Catherine Moste, Isabelle Legastelois, Michel Chevalier, Laurent Thion
-
Publication number: 20090081230Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.Type: ApplicationFiled: July 16, 2008Publication date: March 26, 2009Applicant: HUMAB LLCInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Publication number: 20090068637Abstract: The present application provides monoclonal antibodies that specifically bind to the hemagglutinin of avian influenza virus subtype H5, as well as monoclonal antibodies capable of blocking at least 50% of the hemagglutinin binding activity of these monoclonal antibodies. Such antibodies are useful, for example, in the detection, diagnosis, prevention, and treatment of avian influenza virus. Also provided herein are hybridoma cell lines, isolated nucleic acid molecules, and short peptides related to the monoclonal antibodies provided herein, and pharmaceutical compositions and kits containing the monoclonal antibodies provided herein.Type: ApplicationFiled: January 26, 2007Publication date: March 12, 2009Inventors: Ningshao Xia, Yixin Chen, Shengxiang Ge, Wenxin Luo, Jun Zhang
-
Patent number: 7488477Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: April 30, 2003Date of Patent: February 10, 2009Assignee: Intracel Resources LLCInventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Jr., Brian R. Murphy
-
Patent number: 7485430Abstract: The present invention concerns compositions and methods for evaluating fertility in humans and animals. The invention may also be used to identify reproductive cancers such as testicular cancer. In various embodiments of the invention, an Sptrx-3 enzyme is used as a fertility marker. Sptrx-3 may be detected in accordance with the invention in vitro or in vivo.Type: GrantFiled: April 15, 2005Date of Patent: February 3, 2009Assignee: The Curators of the University of MissouriInventors: Peter Sutovsky, Antonio Miranda-Vizuete
-
Patent number: 7482006Abstract: Provided is an antibody against enterovirus 71 comprising the amino acid sequence shown in SEQ ID NOS: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 or functionally active homologues thereof. Also provided are methods for obtaining the antibody comprising (a) selecting a yeast expressing such an antibody from a yeast library, (b) culturing the yeast under conditions that the antibody is expressed, and (c) recovering the antibody from the culture. Also provided is a process for producing the antibody comprising (a) culturing a host cell under conditions that the antibody is expressed, (b) recovering the antibody from the culture, wherein the host cells are transformed or transfected for expressing the antibody against enterovirus 71. Also provided are pharmaceutical compositions comprising an antibody against enterovirus 71 and a pharmaceutically acceptable carrier or diluent, wherein the antibody has an anti-virus agent or detectable label attached thereto.Type: GrantFiled: April 17, 2006Date of Patent: January 27, 2009Assignee: Development Center for BiotechnologyInventors: Tse-Wen Chang, Jim Jinn-Chyuan Sheu, Lee-Hwa Lo, Nien-Yi Chen, Young-Sun Lin
-
Publication number: 20090022748Abstract: This invention provides an isolated peptide encoded by a nucleic acid which is at least 30 nucleotides in length and has a sequence which uniquely defines a herpesvirus associated with Kaposis' sarcoma, which herpesvirus is present in and recoverable from the HBL-6 cell line (ATCC Accession No. CRL 11762).Type: ApplicationFiled: May 9, 2007Publication date: January 22, 2009Inventors: Yuan Chang, Patrick S. Moore
-
Publication number: 20080274124Abstract: The present invention relates to methods, reagents and kits for detecting of GPR72 polypeptide activity in a sample and identifying agents which modulate polypeptide activity. It further relates to antibodies raised against GPR72. It further relates to substances for preventing, treating and/or alleviating diseases or disorders characterized by dysregulation of GPR72 polypeptide signalling.Type: ApplicationFiled: June 12, 2007Publication date: November 6, 2008Inventors: Sebastien Hannedouche, Marie-Odile Roy
-
Patent number: 7442497Abstract: Methods for determining chronic hepatitis C infection are provided by the present invention. The methods generally involve determining the optical density of fluid samples which have tested positive for hepatitis C infection using an antibody-based assay. The optical density can then be used to determine in a predictive or probability-based manner whether the fluid sample contains chronic hepatitis C infection or whether the fluid sample merely contains antibodies to hepatitis C infection without resorting to costly molecular detection methods. Thus, the present invention permits differentiation between individuals who have cleared hepatitis C infection but still test positive in an antibody-based assay from individuals having chronic hepatitis C infection.Type: GrantFiled: January 18, 2002Date of Patent: October 28, 2008Assignee: Clinical Reference LaboratoryInventor: Robert L. Stout
-
Publication number: 20080248042Abstract: This invention disclosed a monoclonal antibody or a derivative thereof which is cross-reactive against the immunogenic sequence of an infective agent causing a B-cell expansion and IgG-Fc, said infective agent is selected from the group consisting of staphylococcus, HCV, HSV-1, HSV-2, varicella-zoster, CMV, and EBV. The monoclonal antibody is cross-reactive against helicase domain of HCV-NS3 and human IgG-Fc, in particular is cross-reactive against NS31246-1258 and IgG-Fc345-355. Hybridoma producing the antibody of is also provided. Methods for treating an infection, or for treating an autoimmune disease related to an infective agent, said agent causing B-cell expansion, type II mixed cryoglobulinemia, HCV-related neoplastic disease, non-Hodgkin lymphoma are disclosed.Type: ApplicationFiled: April 5, 2007Publication date: October 9, 2008Applicant: IRCCS CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,Inventors: Valli De Re, Maria Paola Simula, Laura Caggiari, Annunziala Gloghini
-
Publication number: 20080219999Abstract: The immunoadhesions of the present invention are useful in treating rhinovirus infections. The immunoadhesions contain a chimeric ICAM molecule and may optionally also contain J chain and secretory compounds. The chimeric ICAM molecule is a fusion protein that has a rhinovirus receptor protein linked to an immunoglobulin protein. This invention also includes the greatly increased and improved method of producing immunoadhesions in plants. Each of the components of an immunoadhesin is produced in a plant cell and thereby assembles within the plant cell. This method of producing the immunoadhesions of the present invention results in the efficient and economic production of these molecules. The present invention also contemplates the production of immunoadhesions in a variety of eukaryotic cells including plants and mammalian cells. The immunoadhesions of the present invention are useful as a therapeutic against the common cold in humans which is caused by rhinoviruses.Type: ApplicationFiled: April 28, 2001Publication date: September 11, 2008Inventors: James William Larrick, Keith Lynn Wycoff
-
Publication number: 20080213284Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.Type: ApplicationFiled: January 10, 2005Publication date: September 4, 2008Inventors: Pele Choi Sing Chong, Shie-Liang Hsieh
-
Publication number: 20080193418Abstract: The invention provides bacteriophages that infect Bacillus bacteria, including Bacillus anthracis, and compositions containing the bacteriophages. The invention also provides methods for using the bacteriophages of the invention to detect, prevent and treat infection of an organism by Bacillus bacteria. Methods and materials to decontaminate a surface or an organism that is contaminated with Bacillus bacteria or Bacillus spores are also provided.Type: ApplicationFiled: June 6, 2005Publication date: August 14, 2008Inventor: Michael H. Walter
-
Publication number: 20080187545Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.Type: ApplicationFiled: June 6, 2007Publication date: August 7, 2008Inventors: Thomas Shenk, Dai Wang
-
Publication number: 20080175849Abstract: Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.Type: ApplicationFiled: December 14, 2007Publication date: July 24, 2008Applicants: Ortho Diagnostics Systems, Inc., Georgetown UniversityInventors: Richard S. Smith, Gary R. Pearson, D. Elliot Parks, Susan Pothen Varghese
-
Patent number: 7402561Abstract: In the US about ? of college women show evidence of HPV infection. The clinical problem may be even larger in developing countries. There are currently no effective therapies for HPV infections, aside from therapeutic cone biopsies, which often are followed by recurrent, progressive lesions. Thus, pharmaceutical compositions and processes for treatment of an HPV infection are detailed. In particular, a pharmaceutical composition for inhibiting growth of a human papilloma virus-infected cell is provided which includes a peptide halomethyl ketone inhibitor of a chymotrypsin or chymotrypsin-like protease and a pharmaceutically acceptable carrier. A preferred inhibitor is AAPFcmk.Type: GrantFiled: March 9, 2005Date of Patent: July 22, 2008Assignee: Clawnor, Inc.Inventors: Gary Clawson, Craig Meyers, David Drubin, Molly McLaughlin-Drubin
-
Patent number: 7396914Abstract: Codon-optimized nucleic acids, polypeptides, and antibodies are described herein.Type: GrantFiled: August 4, 2004Date of Patent: July 8, 2008Assignee: University of MassachusettsInventors: Donna Ambrosino, Hector Hernandez, Thomas Greenough, Katherine Luzuriaga, Mohan Somasundaran, Gregory J. Babcock, William D. Thomas, Jr., John Sullivan
-
Publication number: 20080124359Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.Type: ApplicationFiled: November 16, 2007Publication date: May 29, 2008Applicant: WyethInventors: Chengjin Huang, Jennifer Hess
-
Publication number: 20080108050Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: ApplicationFiled: December 2, 2006Publication date: May 8, 2008Inventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Patent number: 7364737Abstract: Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.Type: GrantFiled: January 29, 2004Date of Patent: April 29, 2008Assignee: The Scripps Research InstituteInventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
-
Publication number: 20080095784Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD64 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating autoimmune disorders, transplant rejection, Graft Versus Host Disease, or cancer and for enhanced presentation of antigen using conjugates of an antigen and an anti-CD64 antibody.Type: ApplicationFiled: June 3, 2005Publication date: April 24, 2008Applicant: MEDAREX, INC.Inventors: Robert Graziano, Karuna Sundarapandiyan
-
Publication number: 20080081047Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.Type: ApplicationFiled: December 6, 2004Publication date: April 3, 2008Inventors: Jody Berry, Steven Jones, Xin Yong Yuan, Mike Gubbins, Anton Andonov, Hana Weingartl, Mike Drebot, Frank Plummer
-
Publication number: 20080075736Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: ApplicationFiled: October 19, 2006Publication date: March 27, 2008Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox
-
Publication number: 20080069839Abstract: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically similar to hSARS virus. The present invention relates to a nucleotide sequence comprising the genomic sequence of the SCoV-like virus. The invention further relates to nucleotide sequences comprising a portion of the genomic sequence of the SCoV-like virus. The invention also relates to the deduced amino acid sequences of the SCoV-like virus. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods.Type: ApplicationFiled: May 24, 2004Publication date: March 20, 2008Inventors: Yi Guan, Bo-Jiang Zheng
-
Patent number: 7345152Abstract: The present invention provides a monoclonal antibody specific for an epitope which is unique to the surface protein component of an inactivated feline immunodeficiency virus (FIV) envelope glycoprotein. Said antibody is useful for the quantification of inactivated FIV or the determination of the potency of an inactivated FIV vaccine.Type: GrantFiled: August 26, 2003Date of Patent: March 18, 2008Assignee: WyethInventor: Chengjin M. Huang
-
Patent number: 7314622Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.Type: GrantFiled: April 14, 2006Date of Patent: January 1, 2008Assignee: Neogenix Oncology, Inc.Inventors: Myron Arlen, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
-
Patent number: 7311906Abstract: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating viral infection.Type: GrantFiled: April 28, 2005Date of Patent: December 25, 2007Assignee: Brigham Young UniversityInventors: Nathaniel Lallatin, Kim L. O'Neill
-
Patent number: 7294703Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: May 14, 2002Date of Patent: November 13, 2007Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
-
Patent number: 7282205Abstract: Chimpanzee monoclonal antibodies and antigen binding fragments including a ?1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.Type: GrantFiled: November 7, 2002Date of Patent: October 16, 2007Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Darren J. Schofield, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 7255986Abstract: The present invention relates to the use of novel nucleotide sequences for the M and N region peptide of the ferret coronavirus and derivative products for the diagnosis and treatment of epizootic catarrhal enteritis (ECE) in ferrets.Type: GrantFiled: January 30, 2003Date of Patent: August 14, 2007Assignee: The Board of Trustees Operating Michigan State UniversityInventors: Roger K. Maes, Annabel G. Wise, Matti Kiupel
-
Patent number: 7217801Abstract: DNA encoding core+1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.Type: GrantFiled: September 17, 2003Date of Patent: May 15, 2007Assignees: Institute Pasteur, Hellenic Pasteur InstituteInventors: Penelope Mavromara, Agoritsa Varaklioto, Urania Georgopoulou
-
Patent number: 7195765Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.Type: GrantFiled: July 6, 2001Date of Patent: March 27, 2007Assignee: N.V. Innogenetics S.A.Inventors: Geert Maertens, Lieven Stuyver
-
Patent number: 7132100Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: June 13, 2003Date of Patent: November 7, 2006Assignee: MedImmune, Inc.Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Patent number: 7108967Abstract: Immunoassays for detecting hepatitis C virus protein and immune complexes between hepatitis C virus protein and antibodies in biological samples, methods of screening blood products for hepatitis C virus, and kits employed therefor are provided.Type: GrantFiled: April 7, 2004Date of Patent: September 19, 2006Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: David Y. Chien, Phillip M. Arcangel
-
Patent number: RE40831Abstract: Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.Type: GrantFiled: June 10, 1997Date of Patent: July 7, 2009Assignee: Yeda Research and Development Co., Ltd.Inventors: Yair Reisner, Shlomo Dagan